Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+

Autor:	Talbot, D, Govindan, R, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, J, Juan-Vidal, O, Stewart, D, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Reck, M, Morgensztern, D, Ong, TJ
Jazyk:	angličtina
Rok vydání:	2020
DOI:	10.1016/j.jtho.2018.08.649
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=od______1064::e3e1116819efc02f3a039ffefc0953a2 https://doi.org/10.1016/j.jtho.2018.08.649 Zobrazit plný text záznamu